Journal
BIOMARKERS IN MEDICINE
Volume 14, Issue 11, Pages 1009-1020Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2019-0587
Keywords
biomarker; gas chromatography; mass spectrometry; intraductal papillary mucinous neoplasms; metabolite; metabolomics; pancreatic cancer; pancreatic cyst; risk factor; screening
Categories
Funding
- Japan Society for the Promotion of Science [16H05227, 18K07266]
- AMED-CREST program run by the Japan Agency for Medical Research and Development [19gm0710013h0506, 19gm0710013h0006]
- Grants-in-Aid for Scientific Research [18K07266, 16H05227] Funding Source: KAKEN
Ask authors/readers for more resources
Aim:The aim of this study was to identify whether metabolite biomarker candidates for pancreatic cancer (PC) could aid detection of intraductal papillary mucinous neoplasms (IPMN), recognized as high-risk factors for PC.Materials & methods:The 12 metabolite biomarker candidates, which were found to be useful to detect PC in our previous study, were evaluated for plasma samples from patients with PC (n = 44) or IPMN (n = 24) or healthy volunteers (n = 46).Results:Regarding the performance of individual biomarkers of PC and PC high-risk IPMN, lysine exhibited the best performance (sensitivity: 67.8%; specificity: 86.9%). The multiple logistic regression analysis-based detection model displayed high sensitivity and specificity values of 92.5 and 90.6%, respectively.Conclusion:Metabolite biomarker candidates for PC are useful for detecting high-risk IPMN, which can progress to PC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available